Re: Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics
We read with interest the paper by Ransohoff ( 1 ) , which addresses the important issue of validity of published results in " -omics " fi elds to assess molecular markers for diagnosis and prognosis of cancer. The commentary was directly motivated by the debate around an initial study that used mass spectroscopy data to discriminate between samples from patients with ovarian cancer and samples from healthy individuals, with reported sensitivity and specifi city of nearly 100%. It discussed many relevant aspects of " -omics " research, including reproducibility and the nature of observational studies. Although there are various issues specifi c to the new technologies, we would like to add that other issues, including the need for external data in validation, are reasonably well understood in the more traditional context of prognostic models ( 2 ) .
The debate itself concerns prediction error rate directly. The true error rate is unknown and has to be estimated from the data at hand. The performance of estimators of the unknown prediction error rate, however, seems to have been discussed only relatively recently in the " -omics " literature ( 3 ) . The key issues surrounding the particular debate described by Ransohoff ( 1 ) are perhaps not the underestimation of the prediction error rate from a narrow statistical point of view, but we argue additionally that some indication of the credibility of the reported prediction error rate, or reported fi ndings in general, should be given in a publication, whenever possible. This is necessary because the amount of intrinsic information in data is critical in determining the validity of a model built from the data ( 2 ) .
In most biomedical publications, variability measures, such as the standard error or confi dence interval, almost always accompany published results. However, " -omics " publications have rarely included variability measurements. Xu and Li ( 4 ) used the bootstrap method to estimate the " rediscovery rate " of the top ranking genes that are differentially expressed under different experimental conditions. Given a target number of genes χ , the rediscovery rate is defi ned as the percentage of the original top χ genes reported from the data that will be rediscovered as top χ genes if the experiment is to be independently replicated. The rediscovery rate can be seen as a measure of variability for the gene ranking problem. In their example of 28 Affymetrix chips to distinguish between two different treatments, the estimated rediscovery rates are about 10% and 53%, respectively, for χ ≤ 100, by use of two different methods to select the top ranking genes. The bootstrap method used to estimate the rediscovery rate in this case is justifi ed as described by Efron and Mammen ( 5 , 6 ) . Bootstrap can also be used to give estimates of variability (e.g., confi dence intervals) for prediction error rate ( 7 ) . We recommend that the associated variability be always reported as part of the result.
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RESPONSE
Xu and Gamet note that confi dence intervals, often reported in research results, are seldom used in studies of diagnosis, though they have recently been advocated ( 1 ) . Reporting confi dence intervals could indicate an important kind of numerical uncertainty around the " central tendency " of a result, but it would not, as Xu correctly notes, address larger problems of bias and overfi tting, and it would not obviate the need to demonstrate reproducibility in an independent group ( 2 , 3 ).
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